TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1546124
Drug: Toloxatone 1000
Normalized name: toloxatone
DrugBank: Toloxatone (DB09245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toloxatone 1000 mg/day
Study: 3096181
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate therapy (variable doses based on initial arterial pH)
Study: 29109363
Drug: 0.033 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.033 mg/kg/day Norditropin® (somatropin)
Study: 29109363
Drug: 0.066 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.066 mg/kg/day Norditropin® (somatropin)
Study: 29109363
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between 0.033 mg/kg/day and 0.066 mg/kg/day
Study: 27298411
Drug: Chemotherapy (epirubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (epirubicin, cisplatin, and fluorouracil)
Study: 19242554
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g/day loading dose for 5 days, followed by 4.8 g/day maintenance)
Study: 19242554
Drug: Placebo (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equivalent number of placebo capsules)
Study: 9931883
Drug: Intraperitoneal active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal active charcoal-mitomycin C therapy (MMC‐CH)
Study: 9931883
Drug: R0 resection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R0 resection with MMC‐CH therapy
Study: 22123270
Drug: Nefopam 30
Normalized name: nefopam 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 30 mg tablet (Acupan®)
Study: 18485252
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of pure natural honey during concomitant chemotherapy and radiotherapy
Study: 18485252
Drug: Concomitant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemotherapy and radiotherapy without honey (Control)
Study: 11721378
Drug: Leunase 6,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leunase 6,000 KU/m2, continuous intravenous injection every day for 8 times
Study: 11721378
Drug: Leunase 6,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leunase 6,000 KU/m2, continuous intravenous injection every other day for 8 times
Study: 7585846
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir (5 mg/kg as a 1-hour i.v. infusion every 24 hours)
Study: 7585846
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir 500 mg every 3 hours (six times daily) for 3 days
Study: 7585846
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir 1,000 mg TID for 3 days
Study: 28750935
Drug: Long-acting cabotegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting cabotegravir 400 mg plus rilpivirine 600 mg (4-week group)
Study: 28750935
Drug: Long-acting cabotegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting cabotegravir 600 mg plus rilpivirine 900 mg (8-week group)
Study: 28750935
Drug: Oral cabotegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cabotegravir plus abacavir-lamivudine (oral treatment group)
Study: 28750935
Drug: Injection-site reactions
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection-site reactions (all groups)
Study: 28750935
Drug: Serious adverse
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serious adverse events (intramuscular groups)
Study: 28750935
Drug: Serious adverse
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serious adverse events (oral treatment group)
Study: 25700386
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid supplements (Control)
Study: 19184686
Drug: Mock prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mock prescriptions
Study: 11956353
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion at 3 kcal min(‐1)
Study: 11956353
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion at 1 kcal min(‐1)
Study: 9589821
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide 0.1% cream pretreatment
Study: 9589821
Drug: Testosterone transdermal
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone transdermal delivery (TTD) without pretreatment
Study: 8028511
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (0.03 mg.kg ideal body weight‐1.d‐1)
Study: 241366
Drug: i.v. diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. diazepam (0.3 mg/kg)
Study: 241366
Drug: i.v. flunitrazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. flunitrazepam (0.03 mg/kg) combined with pethidine (1 mg/kg)
Study: 241366
Drug: i.v. droperidol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. droperidol (5 mg) combined with fentanyl (0.2 mg)
Study: 241366
Drug: i.v. diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. diazepam (0.3 mg/kg) combined with pethidine (1 mg/kg)
Study: 20947493
Drug: distributed constraint‐induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: distributed constraint‐induced therapy (dCIT)
Study: 20947493
Drug: control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: control treatment (CT)
Study: 17309447
Drug: Intralipid infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid infusion for 2 hours
Study: 17309447
Drug: Control infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control infusion (Glycerol)
Study: 2569194
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg dextropropoxyphene napsylat (DP) daily for 16 days
Study: 64951
Drug: Bleomycin (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin (intramuscular injection)
Study: 64951
Drug: Bleomycin (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin (intravenous injection)
Study: 28353144
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg daily for 2 months)
Study: 28353144
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (40 mg for 2 weeks per month for 2 months)
Study: 23738545
Drug: Cognitive processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive processing therapy (1 individual session and 11 group sessions)
Study: 15292036
Drug: Oral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feeding (control group)
Study: 12837670
Drug: Risperidone 2
Normalized name: risperidone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 2 mg/day
Study: 15353388
Drug: Risperidone 0.5
Normalized name: risperidone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 0.5 mg/day
Study: 8261811
Drug: Topical glycolic
Normalized name: glycolate Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glycolic acid lotion
Study: 3949246
Drug: Intra-abdominal instillation
Normalized name: ALCOHOL 80 mL in 100 mL INTRA-ABDOMINAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-abdominal instillation of bupivacaine 2 mg/kg bw
Study: 3052266
Drug: Bromocriptine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (up to 30 mg per day)
Study: 31154887
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour language therapy (CBLT) programme delivered in 24 group sessions over 12 weeks
Study: 23433852
Drug: Once-daily DRV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily DRV/r
Study: 23433852
Drug: Twice-daily DRV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily DRV/r
Study: 20840345
Drug: Licochalcone A
Normalized name: Licochalcone A
DrugBank: Licochalcone A (DB19281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licochalcone A (LA) lotion, applied twice daily for 6 weeks
Study: 20840345
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) lotion, applied twice daily for 6 weeks
Study: 17301824
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 mg/daily)
Study: 17301824
Drug: Combined (losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined (losartan 50 mg/daily + ramipril 5 mg/daily)
Study: 9932142
Drug: GLA +
Normalized name: GLA
DrugBank: Gamolenic acid (DB13854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLA + EPA (continued treatment)
Study: 3056506
Drug: Metronidazole treatment
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole treatment (2 g single doses on days 1 and 3) for male partners
Study: 3056506
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for male partners
Study: 28669288
Drug: MOMCare collaborative
Normalized name: ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MOMCare collaborative care depression intervention (choice of brief interpersonal psychotherapy or pharmacotherapy or both)
Study: 22878873
Drug: Sequential HRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential HRP scoring protocol (automatic and then manual for residual cases)
Study: 19338158
Drug: Salvia injection
Normalized name: SALVIA OFFICINALIS
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvia injection (SI) plus composite amino acid (CAA) for 7 days
Study: 15255164
Drug: irinotecan in
Normalized name: irinotecan Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan in combination with gemcitabine, taxanes, and other new agents
Study: 15255164
Drug: irinotecan combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan combined with a platinum agent
Study: 12587182
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (2.5%) infusion
Study: 12587182
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (0.9%) infusion
Study: 9577356
Drug: Subcutaneous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous octreotide 250 micrograms twice daily
Study: 3285637
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D2 supplementation (400 IU, 5-7 times weekly)
Study: 30355512
Drug: Daily TPTD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily TPTD for 24 months (Rx-Naïve)
Study: 30355512
Drug: Daily TPTD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily TPTD for 24 months (ALN-Rx)
Study: 28980452
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of furosemide (initial dose 80 mg/day, can be doubled if poor response)
Study: 28980452
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of furosemide (twice-daily bolus injection)
Study: 28980452
Drug: High diuretic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High diuretic dose (furosemide >120 mg/day)
Study: 28980452
Drug: Low diuretic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low diuretic dose (furosemide ≤120 mg/day)
Study: 19847131
Drug: Constraint-induced movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-induced movement therapy combined with an intensive rehabilitation program
Study: 11905959
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (600 mg alpha‐tocopherol, 1000 mg ascorbic acid, 32 mg beta‐carotene)
Study: 7944656
Drug: Adjuvant total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant total parenteral nutrition
Study: 7944656
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant total parenteral nutrition (Control)
Study: 2904825
Drug: Bisoprolol (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (10‐20 mg)
Study: 2904825
Drug: Atenolol (50‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50‐100 mg)
Study: 27575791
Drug: Treatment retention
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment retention
Study: 16379563
Drug: Flax fiber
Normalized name: Flax fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flax fiber supplement (15 g/day)
Study: 16379563
Drug: Psyllium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium supplement (10.4 g/day)
Study: 10561205
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with tamoxifen
Study: 10561205
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without tamoxifen
Study: 10561205
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with or without tamoxifen
Study: 3889258
Drug: Furosemide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (1 mg/kg/12 hr intravenously or 2 mg/kg/12 hr orally)
Study: 30372830
Drug: MgSO4 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgSO4 (50 mg/kg infused intravenously within 15 min)
Study: 19703327
Drug: DHA (220
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (220 mg/d)
Study: 19703327
Drug: DHA+AA (220
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA+AA (220 mg each/d)
Study: 12377399
Drug: Theophylline (0.66
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (0.66 mg/kg, maximum dose of 500 mg)
Study: 12377399
Drug: Schizophrenia group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schizophrenia group (baseline results from 17 drug-treated patients)
Study: 10463785
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose (1 ml 30% glucose) prior to skin puncture
Study: 10463785
Drug: Heel stick
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heel stick without oral glucose
Study: 10463785
Drug: Venepuncture without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venepuncture without oral glucose
Study: 2688080
Drug: Tenoxicam suppositories
Normalized name: tenoxicam Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam suppositories (20 mg once daily)
Study: 2688080
Drug: Piroxicam suppositories
Normalized name: piroxicam Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam suppositories (20 mg once daily)
Study: 31926605
Drug: Intravenous siponimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous siponimod (0.25 mg/3 h)
Study: 31926605
Drug: Intravenous siponimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous siponimod (1 mg/24 h)
Study: 31926605
Drug: Oral siponimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral siponimod (0.25 mg)
Study: 31926605
Drug: Intravenous siponimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous siponimod (0.25 mg/3 h) and Oral siponimod (0.25 mg)
Study: 11130251
Drug: IV granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV granisetron (G) 3 mg once a day
Study: 11130251
Drug: IV tropisetron
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tropisetron (T) 5 mg once a day
Study: 11130251
Drug: IV ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ondansetron (O) 8 mg twice daily
Study: 11130251
Drug: IV granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV granisetron (G)
Study: 8227493
Drug: Fluvoxamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine treatment in OCD patients with chronic tic disorder
Study: 8227493
Drug: Fluvoxamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine treatment in OCD patients without chronic tic disorder
Study: 30280640
Drug: Transcatheter mitral-valve
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter mitral-valve repair plus medical therapy (device group)
Study: 24729507
Drug: Azithromycin 1
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1 g
Study: 7580297
Drug: Solvent solution
Normalized name: solvent yellow 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solvent solution
Study: 1935285
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler (MDI) via spacer (InspirEase)
Study: 28494906
Drug: Morphine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine group (GM): 20ml 0.5% bupivacaine + 10mg morphine sulphate diluted in 20ml saline
Study: 28494906
Drug: Morphine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine group (GM)
Study: 26920896
Drug: Zedoary herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zedoary herbal tea (ZHT) T1 (500 mg ZRDP)
Study: 26920896
Drug: Zedoary herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zedoary herbal tea (ZHT) T2 (1 g ZRDP)
Study: 26920896
Drug: Zedoary herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zedoary herbal tea (ZHT) T3 (1.5 g ZRDP)
Study: 7699642
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 1.5 g/kg every 2 weeks for 2 months, then monthly for 4 months (total: up to 9 infusions over 6 months)
Study: 3322590
Drug: Mitoxantrone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (10 mg/m2) with cyclophosphamide (500 mg/m2) and 5-fluorouracil (500 mg/m2)
Study: 3322590
Drug: Doxorubicin (50-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (50-60 mg) with cyclophosphamide (500 mg/m2) and 5-fluorouracil (500 mg/m2)
Study: 27555133
Drug: Intravenous 1g
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 1g paracetamol (Group P)
Study: 27555133
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution (Group C)
Study: 12611908
Drug: 15 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg/day ursodeoxycholic acid (UDCA) for 20 days
Study: 12611908
Drug: No bile
Normalized name: bile salts
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bile acid supplement (control)
Study: 10575906
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E combined with potent inhibitors of platelet aggregation
Study: 11144988
Drug: Rofecoxib (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (75 mg once daily)
Study: 2654206
Drug: MEFAE sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEFAE sodium 720 mg daily
Study: 2654206
Drug: DMFAE 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMFAE 240 mg daily
Study: 2654206
Drug: MEFAE sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEFAE sodium up to 240 mg daily
Study: 968056
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg 15(S)‐15 methyl PGF2alpha in viscous medium (Tylose)
Study: 968056
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg 15(S)‐15 methyl PGF2alpha in viscous medium (Hyskon)
Study: 968056
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg 15(S)‐15 methyl PGF2alpha in non‐viscous medium repeated at 12 hours
Study: 968056
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg 15(S)‐15 methyl PGF2alpha in viscous medium
Study: 29058097
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy (cisplatin 80 mg/m2 for six cycles plus capecitabine 1000 mg/m2 orally bid days 1-14 or 5-fluorouracil 800 mg/m2/day continuous IV infusion days 1-5 every 3 weeks)
Study: 24598306
Drug: Methylprednisolone (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (two intravenous doses of 250 mg each)
Study: 17985809
Drug: Mindful Awareness
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindful Awareness in Body-oriented Therapy (MABT)
Study: 17150108
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA), mean dose of 850 mg/d for 18 months (range 6-27 months)
Study: 14695410
Drug: Placebo (660
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (660 ml beverage with artificial sweeteners)
Study: 1796197
Drug: morniflumate combined
Normalized name: morniflumate
DrugBank: Morniflumate (DB09285)
Approvals — FDA: no, EMA: no, PMDA: no
Description: morniflumate combined with amoxicillin
Study: 1796197
Drug: imidazole-2-hydroxybenzoate combined
Normalized name: imidazole-2-hydroxybenzoate
DrugBank: Imidazole salicylate (DB13860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: imidazole-2-hydroxybenzoate combined with amoxicillin
Study: 1796197
Drug: antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotic therapy alone
Study: 6666232
Drug: ISDN (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN (3 mg intracoronary)
Study: 6666232
Drug: ASA (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA (1.0 g intravenous and 100 mg intracoronary)